Breaking News Instant updates and real-time market news.

LIVN

LivaNova

$72.45

-2.845 (-3.78%)

09:06
10/23/19
10/23
09:06
10/23/19
09:06

LivaNova announces publication of chronic epilepsy study

LivaNova announced the publication of a new study in Neurology, which suggests that chronic epilepsy may be associated with key measures of sudden cardiac death risk. This is the third in a series of studies to evaluate cardiac electrical instability in patients with chronic epilepsy, but the first to compare the cardiac impact of the disease among patients with chronic epilepsy to those who are newly diagnosed. The study in Neurology evaluated established markers of sudden cardiac death risk, T-wave alternans, or TWA, and heart rate variability, or HRV, in patients with chronic epilepsy compared to patients with newly diagnosed epilepsy. Using data recorded on ambulatory electrocardiographic monitors, the investigators assessed whether cardiac electrical instability indicated by TWA and abnormal autonomic tone measured by HRV result from recurrent seizures. Results from the analysis showed that chronic epilepsy is associated with higher TWA levels and simultaneously with lower HRV, suggesting autonomic dysfunction or higher sympathetic tone.

  • 30

    Oct

  • 21

    Nov

LIVN LivaNova
$72.45

-2.845 (-3.78%)

06/05/19
PIPR
06/05/19
NO CHANGE
Target $90
PIPR
Overweight
Piper recommends looking at LivaNova despite possible 'messy' Q2
Piper Jaffray analyst Matt O'Brien, while acknowledging the company's Q2 "could again be messy," encourages investors to take a look at LivaNova shares. After reviewing Epidiolex scripts in Q2, the analyst found that uptake of the drug is still growing, though he adds the "curve is clearly flattening this quarter." The raw number of scripts filled suggests that the disruption seen at LivaNova may be more related to buzz around this cannabis product as opposed to vagus nerve stimulation candidates actually switching to Epidiolex, O'Brien tells investors in a research note. He expects LivaNova's Neuromod segment to rebound following a "disappointing" Q1 and keeps an Overweight rating on the company's shares with a $90 price target.
07/31/19
PIPR
07/31/19
NO CHANGE
PIPR
Overweight
LivaNova core visibility, TRD opportunity underappreciated, says Piper Jaffray
Piper Jaffray analyst Matt O'Brien said LivaNova's report of some stabilization in the Neuromod franchise was a key takeaway from the company's Q2 results. He maintains his view that the Neuromod franchise will rebound in the second half of the year and that TRD is receiving minimal value despite the fact that the first enrollment in the TRD trial is still on track for late this quarter, O'Brien tells investors. He keeps an Overweight rating on LivaNova shares.
09/06/19
PIPR
09/06/19
NO CHANGE
PIPR
Piper Jaffray says positive updates continue for LivaNova
Piper Jaffray analyst Matt O'Brien spoke to LivaNova's management following CMS approval the company's treatment-resistant depression, or TRD, protocol, and he views the updates positively and continues to see TRD as "one of the most exciting and large pipeline opportunities" for the company. O'Brien was also positive on the company's turnaround of its core Neuromod business due to its "solid" Q2 results, and maintained an Overweight rating and $90 price target on LivaNova shares.
09/29/19
PIPR
09/29/19
NO CHANGE
Target $90
PIPR
Overweight
LivaNova first patient enrollment in RECOVER 'an important step,' says Piper Jaffray
Piper Jaffray analyst Matt O'Brien notes that LivaNova announced it had enrolled the first patient in its CMS approved RECOVER clinical study. Although the timing is in-line with management's expectations, there had been some concern that it would slip, he notes, adding that the announcement is "certainly positive" and "an important step" for the company's topline outlook. On the whole, the analyst believes the announcement serves as a starting point for eventual coverage. O'Brien reiterates an Overweight rating and $90 price target on the shares.

TODAY'S FREE FLY STORIES

ALPMY

Astellas Pharma

$0.00

(0.00%)

20:02
11/20/19
11/20
20:02
11/20/19
20:02
Hot Stocks
Astellas Pharma, Welldoc enter into Digital Therapeutics alliance »

Astellas Pharma and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

PYPL

PayPal

$104.09

-0.85 (-0.81%)

19:52
11/20/19
11/20
19:52
11/20/19
19:52
Recommendations
PayPal analyst commentary  »

PayPal's Honey…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 21

    Nov

  • 10

    Dec

SQM

SQM

$23.41

-0.35 (-1.47%)

19:42
11/20/19
11/20
19:42
11/20/19
19:42
Earnings
SQM reports Q3 EPS 23c, consensus 26c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

TNAV

TeleNav

$4.92

0.07 (1.44%)

19:37
11/20/19
11/20
19:37
11/20/19
19:37
Hot Stocks
TeleNav CEO buys 150K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

CRSP

Crispr Therapeutics

$67.31

-1.15 (-1.68%)

19:29
11/20/19
11/20
19:29
11/20/19
19:29
Syndicate
Breaking Syndicate news story on Crispr Therapeutics »

Crispr Therapeutics 4.25M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 21

    Nov

PFGC

Performance Food Group

$44.66

-0.13 (-0.29%)

19:26
11/20/19
11/20
19:26
11/20/19
19:26
Syndicate
Performance Food Group upsized 10.1M share offering said to price at $44.25 »

Report from Bloomberg. …

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 21

    Nov

INVH

Invitation Homes

$30.05

0.13 (0.43%)

19:10
11/20/19
11/20
19:10
11/20/19
19:10
Periodicals
Breaking Periodicals news story on Invitation Homes »

Invitation Homes stock…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

KRTX

Karuna Therapeutics

$108.42

-15.58 (-12.56%)

19:03
11/20/19
11/20
19:03
11/20/19
19:03
Syndicate
Karuna Therapeutics 2.6M share Secondary priced at $96.00 »

The deal priced below the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

GOOG

Alphabet

$1,302.26

-12.45 (-0.95%)

, GOOGL

Alphabet Class A

$1,301.34

-11.25 (-0.86%)

18:58
11/20/19
11/20
18:58
11/20/19
18:58
Hot Stocks
Google to limit election ads audience targeting, will prohibit 'deep fakes' »

Alphabet's Google…

GOOG

Alphabet

$1,302.26

-12.45 (-0.95%)

GOOGL

Alphabet Class A

$1,301.34

-11.25 (-0.86%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CAN

Canaan

$0.00

(0.00%)

18:56
11/20/19
11/20
18:56
11/20/19
18:56
Syndicate
Canaan 10M share IPO priced at $9.00 »

The deal priced at low…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

NUAN

Nuance

$16.60

0.11 (0.67%)

, CPRT

Copart

$84.69

-1.64 (-1.90%)

18:51
11/20/19
11/20
18:51
11/20/19
18:51
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: Nuance…

NUAN

Nuance

$16.60

0.11 (0.67%)

CPRT

Copart

$84.69

-1.64 (-1.90%)

LB

L Brands

$16.00

-1.19 (-6.92%)

JACK

Jack in the Box

$84.89

-0.08 (-0.09%)

SONO

Sonos

$13.87

-0.635 (-4.38%)

NTGN

Neon Therapeutics

$1.44

-0.04 (-2.70%)

TIF

Tiffany

$123.32

-0.16 (-0.13%)

UBER

Uber

$28.02

0.99 (3.66%)

LZB

La-Z-Boy

$36.23

-0.265 (-0.73%)

CUB

Cubic

$73.63

0.8 (1.10%)

NTES

NetEase

$287.68

-1.09 (-0.38%)

OPTN

Optinose

$11.42

0.84 (7.94%)

MTEM

Molecular Templates

$8.28

0.19 (2.35%)

PYPL

PayPal

$104.09

-0.85 (-0.81%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 20

    Nov

  • 20

    Nov

  • 20

    Nov

  • 20

    Nov

  • 21

    Nov

  • 21

    Nov

  • 21

    Nov

  • 21

    Nov

  • 21

    Nov

  • 21

    Nov

  • 04

    Dec

  • 05

    Dec

  • 05

    Dec

  • 06

    Dec

  • 10

    Dec

  • 10

    Dec

  • 21

    Nov

  • 21

    Nov

WNC

Wabash

$15.05

-0.2 (-1.31%)

18:48
11/20/19
11/20
18:48
11/20/19
18:48
Initiation
Wabash initiated  »

Wabash initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALSN

Allison Transmission

$45.51

-0.56 (-1.22%)

18:47
11/20/19
11/20
18:47
11/20/19
18:47
Initiation
Allison Transmission initiated  »

Allison Transmission…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NAV

Navistar

$30.97

-0.97 (-3.04%)

18:47
11/20/19
11/20
18:47
11/20/19
18:47
Initiation
Navistar initiated  »

Navistar initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PCAR

Paccar

$78.85

-0.59 (-0.74%)

18:47
11/20/19
11/20
18:47
11/20/19
18:47
Initiation
Paccar initiated  »

Paccar initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CMI

Cummins

$180.59

-2.36 (-1.29%)

18:46
11/20/19
11/20
18:46
11/20/19
18:46
Initiation
Cummins initiated  »

Cummins initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

VMC

Vulcan Materials

$140.72

-0.485 (-0.34%)

18:45
11/20/19
11/20
18:45
11/20/19
18:45
Initiation
Vulcan Materials initiated  »

Vulcan Materials…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SUM

Summit Materials

$24.18

0.3 (1.26%)

18:45
11/20/19
11/20
18:45
11/20/19
18:45
Initiation
Summit Materials initiated  »

Summit Materials…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

MLM

Martin Marietta

$263.10

1.36 (0.52%)

18:45
11/20/19
11/20
18:45
11/20/19
18:45
Initiation
Martin Marietta initiated  »

Martin Marietta initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

THC

Tenet

$31.36

-0.38 (-1.20%)

18:33
11/20/19
11/20
18:33
11/20/19
18:33
Hot Stocks
Tenet General Counsel sells 65K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PFPT

Proofpoint

$119.56

1.25 (1.06%)

18:23
11/20/19
11/20
18:23
11/20/19
18:23
Hot Stocks
Proofpoint's Salle sells 10,479 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 12

    Dec

LVMUY

LVMH

$0.00

(0.00%)

, TIF

Tiffany

$123.32

-0.16 (-0.13%)

18:21
11/20/19
11/20
18:21
11/20/19
18:21
Periodicals
Tiffany gives LVMH access to its books after raised bid, Reuters says »

LVMH (LVMUY) has…

LVMUY

LVMH

$0.00

(0.00%)

TIF

Tiffany

$123.32

-0.16 (-0.13%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

CPRT

Copart

$84.69

-1.64 (-1.90%)

18:05
11/20/19
11/20
18:05
11/20/19
18:05
Earnings
Copart reports Q1 non-GAAP EPS 65c, consensus 59c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

  • 06

    Dec

NTES

NetEase

$287.68

-1.09 (-0.38%)

18:04
11/20/19
11/20
18:04
11/20/19
18:04
Earnings
NetEase reports Q3 adjusted ADS $5.12, consensus $3.12 »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

LVMUY

LVMH

$0.00

(0.00%)

, TIF

Tiffany

$123.32

-0.16 (-0.13%)

17:58
11/20/19
11/20
17:58
11/20/19
17:58
Periodicals
LVMH, Tiffany in deal talks after LVMH boosts bid, Bloomberg reports »

LVMH (LVMUY) and Tiffany…

LVMUY

LVMH

$0.00

(0.00%)

TIF

Tiffany

$123.32

-0.16 (-0.13%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.